Company profile: ProMIS Neurosciences
1.1 - Company Overview
Company description
- Provider of therapeutic products and diagnostic devices for misfolded protein diseases, including PMN310 (humanized IgG1 antibody targeting toxic amyloid beta oligomers for Alzheimer’s), PMN267 (preclinical antibody targeting misfolded TDP-43 for ALS), PMN400 (lead vaccine candidate for synucleinopathies including MSA, Parkinson’s disease, and Lewy Body Dementia), and RACK1 targeting for ALS/FTLD.
Products and services
- PMN310: A humanized IgG1 antibody that targets toxic amyloid beta oligomers, intended for Alzheimer’s disease treatment, developed for misfolded protein diseases
- PMN400: A lead vaccine candidate against multiple synucleinopathies, including MSA, Parkinson’s disease, and Lewy Body Dementia, developed for misfolded protein diseases
- PMN267: An antibody advancing through preclinical development that targets misfolded forms of TDP-43 for ALS treatment, developed for misfolded protein diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProMIS Neurosciences
Neuron Bio
HQ: Spain
Website
- Description: Provider of innovative biosolutions: AlzTEST blood biomarker diagnostic for Alzheimer’s; Omega-3 DHA microalgae oil for functional foods and nutraceuticals; MicroBiOil platform for microbial oils and oleochemicals; Microbiotools by Neol for bioprocess development; custom R&D in biomedicine, toxicology and agro-food; and a drug discovery platform for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuron Bio company profile →
Tris Pharma
HQ: United States
Website
- Description: Provider of specialty generic pharmaceuticals leveraging its LiquiXR drug delivery technology for sustained-release formulations, including ADHD treatments with flexible dosing for patients aged 6+, a portfolio of 10 generic products with 20+ in development, technology licensing of its delivery technologies, and partnerships to enhance product development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tris Pharma company profile →
Prestwick Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic pharmaceutical drugs for chronic central nervous system diseases, offering products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea. Founded in 2002 and based in Washington, District of Columbia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prestwick Pharmaceuticals company profile →
Braeburn
HQ: United States
Website
- Description: Provider of opioid use disorder solutions, including BRIXADI, a weekly and monthly injectable medication for moderate to severe OUD, and an Investigator-Initiated Trials program that supports independent research to advance medical and scientific understanding of its products and related therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Braeburn company profile →
Tissuemed
HQ: United Kingdom
Website
- Description: Provider of tissue-based therapeutic devices and surgical bioadhesive films, including the first tissue heart valve to gain regulatory approval in Europe. Specializes in adhesive films to prevent air, blood and fluid leaks encountered in surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissuemed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProMIS Neurosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProMIS Neurosciences
2.2 - Growth funds investing in similar companies to ProMIS Neurosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProMIS Neurosciences
4.2 - Public trading comparable groups for ProMIS Neurosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →